Due to their capacity to cross-present tumor antigens to naïve CD8 T cells, cDC1 have been the focus of many immuno-oncology studies, and are thoroughly reviewed elsewhere (Audsley et al., 2020; Noubade et al., 2019). This evidence concerns the gene CD8A and neoplasm.